ACOR — Acorda Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.68m
- $157.84m
- $117.63m
- 26
- 61
- 28
- 31
Annual cashflow statement for Acorda Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -273 | -99.6 | -104 | -65.9 | -253 |
| Depreciation | |||||
| Non-Cash Items | 152 | 9.24 | 3.72 | 10.5 | 218 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -41.4 | -12 | 24.9 | 1.7 | -10.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -128 | -61 | -41.3 | -20.9 | -14 |
| Capital Expenditures | -90.4 | -4.39 | -0.191 | -0.136 | -0.264 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 89.9 | 63.8 | 74 | 0 | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | -0.505 | 59.4 | 73.8 | -0.136 | -0.264 |
| Financing Cash Flow Items | -4.67 | -1.07 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -60.5 | -1.67 | -69.7 | 0 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -189 | -2.3 | -37.7 | -20.5 | -14.1 |